Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma

─ Presented at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting ─  …

Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma

─ Presented at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting ─  …

Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) in Europe

Oxford, UK – May 9, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics celebrates five year anniversary

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

First production and administration of Axumin® (fluciclovine (18F)) in Italy.

Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…